{'fraction_non_alphanumeric': 0.05191873589164785, 'fraction_numerical': 0.033860045146726865, 'mean_word_length': 4.2485207100591715, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MMP-9 (-1562 C:T) polymorphism as a biomarker of susceptibility to severe pre-eclampsia.

AIM
To investigate the role of MMP-9 (-1562 C:T) polymorphism as a biomarker for susceptibility to pre-eclampsia.


PATIENTS & METHODS
MMP-9 variants were detected in 160 women with mild and severe pre-eclampsia and 112 healthy pregnant women.


RESULTS
A significantly higher frequency of MMP-9 CT genotype was observed in both mild and severe pre-eclamptic women compared with controls. In the presence of CT + TT genotype the risk of severe pre-eclampsia increased 2.37-fold (p = 0.02). In women with early-onset pre-eclampsia the frequency of MMP-9 CT + TT genotype was significantly higher (p = 0.045) compared with those with late-onset pre-eclampsia.


CONCLUSION
The MMP-9 variant could be a useful biomarker of susceptibility to severe pre-eclampsia and early-onset severe pre-eclampsia.